At its annual general meeting of June 1, 2007, the Berlin-based biotech company MOLOGEN AG has announced far reaching strategic decisions. Prof. Wittig announced to leave the Board of Directors at the end of this year when his contract expires, to attend to intensified research activities. Prof. Wittig will join the newly founded Scientific Advisory Board of MOLOGEN and thus keep a close connection to the company.
